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Abstract: Bacterial vaginosis is a common cause of malodorous vaginal discharge. It is also 
associated with sexually transmitted infections and adverse pregnancy outcomes. The magnitude 
of the gynecological and obstetrical consequences has stimulated therapeutic research and led to 
the testing of several therapies. The objective of this work is to present the currently available 
therapeutic strategies for the treatment of bacterial vaginosis and associated recommendations, 
and discuss the emerging therapies.
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Introduction
Bacterial vaginosis (BV) is a common cause of malodorous vaginal discharge in women 
of reproductive age.1 Women’s awareness of BV is low and often they self-medicate 
with antifungals before presenting very late when symptoms have become   intolerable. 
However, many affected women are asymptomatic.1 The exact etiology remains 
elusive, although some authors have proposed a complex interaction between the 
numerous components of the vaginal microbial ecosystem and their human host.2 
Multiple risk factors for BV infection have been hypothesized, including vaginal 
douching, African-American race, multiple or new sexual partners, and women who 
have sex with women.1,3 Inversely, hormonal contraceptive use, male circumcision, 
and consistent condom use reduce the incidence of BV .1,4,5
BV was first described in 1955 by Gardner and Dukes who reported a strong 
correlation between BV and the presence of Gardnerella vaginalis.6 However, progress 
in defining the composition of the vaginal microbiome had to await the development 
of new molecular techniques. These implicated not one bacterial species but numerous 
bacteria in BV and increased our understanding of the characteristic shift in the normal 
vaginal microbiota from a predominance of protective lactobacilli to pathogenic 
anaerobic bacteria.7 The resident Lactobacillus species are replaced by an overgrowth 
of vaginal anaerobes or Gram-negative bacteria including Gardnerella vaginalis, 
Atopobium vaginae, bacterial vaginosis-associated bacteria, Megasphaera species, 
Mycoplasma hominis, Mobiluncus species, Ureaplasma urealyticum, Prevotella, and 
Peptostreptococcus species.8 Moreover, BV-associated bacteria have been shown to 
form a prolific polymicrobial biofilm, the main component of which was found to 
be G. vaginalis and A. vaginae, that adheres to the vaginal epithelium.9 These recent 
advances have facilitated the detection and the identification of bacteria without the 
need for cultivation. Some of these bacteria have not previously been described or International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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well characterized and have led some authors to propose new 
diagnostic tools based on molecular biological techniques.7,10 
Nevertheless, the clinical Amsel criteria and the Gram 
stain-based Nugent score remain widely used. Clinical 
diagnosis is based on the combination of any three of the 
following four criteria: vaginal pH . 4.5, thin homogeneous 
vaginal discharge, clue cells on microscopic examination 
of vaginal fluid, and a “fishy” amine odor.11 A subjective 
clinical diagnosis is of limited value in assessing women 
in the general population as most of women with BV are 
asymptomatic. Microbiological diagnosis is based on Gram 
staining graded according to the Nugent score that reflects 
the presence of normal (score of 0–3) or intermediate flora 
(score of 4–6), or BV (score of 7–10).12 The artificial category 
intermediate flora has further complicated the diagnostic 
approach since a considerable percentage of women tested 
fall into this category, the precise clinical implications of 
which, either none or pathology inducing, remain largely 
uncharacterized.
Interest in BV has grown since it was found to associate 
with an increased susceptibility to sexually transmitted 
infections, herpes simplex viruses, human papillomavirus, 
and human immunodeficiency virus (HIV).13,14 BV has also 
been associated with postoperative infection and adverse 
pregnancy outcomes including premature rupture of 
membranes, premature labor and delivery, intra-amniotic 
infection, and low-birth-weight infants.15,16
The magnitude of these gynecological and obstetrical 
consequences has stimulated a research effort towards thera-
peutic development from which several therapies have been 
tested. However, evaluation of BV therapeutic studies reveals 
a major problem in that most used some or all of the clinical 
Amsel criteria, the Gram stain results, or a combination of 
both to define the diagnosis and the proposed cure, whereas a 
few others used the criteria defined by the US Food and Drug 
Administration (FDA) to perform the examination to evaluate 
the therapeutic response based on a combination of both the 
clinical outcome and the Gram stain results.17 Making com-
parisons between these studies is therefore problematic. The 
main aim here was to present the currently available therapeu-
tic strategies for BV and their associated recommendations, 
as well as discuss the emerging therapies. For this review, 
I performed searches of MEDLINE (2000 to present) using the 
keywords “bacterial vaginosis”,   “treatment”, “  prevention”, 
and “recurrent bacterial vaginosis” to identify all English-
language articles concerning current and emerging therapies 
for BV . I observed the current guidelines published by the 
US Centers for Disease Control.
Antibiotic therapy
Metronidazole
Metronidazole is a nitroimidazole antimicrobial agent used 
to manage protozoal infections such as trichomoniasis and 
anaerobic infections.18 Since the early 1980s, metronidazole 
has been used widely in the treatment of BV with good 
  clinical results. Various preparations allowing a vaginal 
or oral administration and different regimens have been 
studied.
Metronidazole vs placebo
Local (single-dose 100 mg, 250 mg, and 500 mg vaginal 
metronidazole tablets; or 0.75% metronidazole gel once or 
twice daily for 5 days) and oral metronidazole (400 mg twice 
daily for 7 days; or 500 mg three times daily for 10 days) have 
lower rates of treatment failure compared with placebo.19,20 
The cure rates of women given antibiotics were higher 
(58%–100%) than the cure rates of women given placebo 
(5%–29%) when evaluated 4 weeks after treatment. The 
cure rates varied widely according to the diagnostic criteria 
for abnormal flora at inclusion, the definition of cure and 
treatment failure, and length of time post-therapy before the 
follow-up visit.
Routes of administration
Two randomized controlled studies directly compared the 
efficacy of vaginal (0.75% metronidazole vaginal gel 5 g, 
twice daily for 5 days) vs oral regimens (500 mg twice 
daily for 7 days). The efficacy of vaginal and oral regimens 
was similar when evaluated 2 weeks and 5 weeks after 
treatment.21,22 However, the vaginal regimen was associated 
with less gastrointestinal complaints (33% vs 52%).21
Duration of oral regimens
In 1992, a meta-analysis was conducted on ten studies 
comparing different oral metronidazole regimens.23 The 
women were categorized according to the duration of oral 
metronidazole treatment: (1) 2 g single dose, (2) 2 g single 
dose daily for 2 days, (3) 400 mg twice or three times daily 
for 5 days, (4) 500 mg twice daily for 7 days. The cure rates 
ranged from 85% to 87% with no significant difference 
among the groups. Furthermore, no difference was found in 
the recurrence rates 1 month following single-dose, 5-day 
or 7-day regimens. The results of this meta-analysis were 
however criticized and in 1999, Joesoef and collaborators 
performed another meta-analysis including only the four 
studies that compared the single dose (2 g) and the 7-day 
regimens. They demonstrated that the clinical efficacy of International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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the 7-day regimen is superior to the single-dose regimen 
with cumulative cure rates 3–4 weeks after completion of 
treatment of 82% for the 7-day regimen vs 62% for the 
single-dose regimen.24 A more recent review also concluded 
that the 7-day regimen of metronidazole is superior to the 
single-dose regimen leading the authors to recommend it as 
the first-line regimen in the treatment of BV. More recently, 
a randomized trial examined whether extending the duration 
of metronidazole therapy to 14 days was superior to the 
7-day regimen by enhancing the cure rates for BV. Cure 
rates were significantly improved with the 14-day regimen at 
the 7-day follow-up visit (45% vs 63%). However, the cure 
rates were equal at the 21-day follow-up visit, suggesting 
that relapse or reinfection had occurred.25 Extending the 
duration of metronidazole therapy was not associated with 
an increase of vaginal candidiasis or of gastrointestinal 
adverse effects.25
Adverse effects
Metronidazole therapy is associated with side effects 
including gastrointestinal effects (metallic taste in the 
mouth, nausea, vomiting) and candida infection. However 
a recent meta-analysis did conclude that when applied 
topically, metronidazole was not significantly associated 
with candidiasis.20 Such side effects have been used to 
support single-dose therapy of oral metronidazole or 
topical metronidazole.26 They may also be responsible for 
difficulties adhering to a 7-day course of treatment and 
subsequently result in treatment failure. Incomplete cure 
would be associated with an increased risk of recurrence or 
the development of metronidazole resistance. Since vaginal 
regimens have been associated with fewer gastrointestinal 
complaints (33% vs 52%),21 vaginal metronidazole may be 
an alternative to oral metronidazole.
Clindamycin
Clindamycin is a second antimicrobial agent for the treatment 
of BV . This lincosamide antibiotic, a subclass of the larger 
family of macrolide antibiotics, has various treatment 
preparations including vaginal (ovule and cream) and oral.
Clindamycin vs placebo
In a recent meta-analysis, intravaginal treatment (0.1%, 
1%, 2% clindamycin cream twice daily for 5 days; 2% 
clindamycin cream at bedtime for 7 days) showed benefits 
to BV treatment with lower treatment failure compared 
with placebo (relative risk: 0.25; 95% confidence interval: 
0.16–0.37).20
Routes of administration
Only one study has evaluated the use of oral clindamycin 
vs intravaginal administration. According to this study, oral 
administration of 450 mg clindamycin three times daily and 
2% clindamycin in vaginal cream 5 g once daily, for 7 days 
had similar cure rates.27
Ovules vs cream
One randomized study compared the efficacy of clindamycin 
vaginal ovules (100 mg daily for 3 days) with clindamycin 
vaginal cream (5 g at bedtime for 7 days) for the treatment 
of BV .28 The cure rates were similar: 53.7% for the ovule 
group and 47.8% for the cream group. Similarly, a single 
dose of clindamycin vaginal cream was found to be equiva-
lent in terms of safety and efficacy to a 7-dose regimen of 
vaginal cream.29
Clindamycin vs metronidazole
In the recent Cochrane review, topical clindamycin (2% 
clindamycin cream 5 g at bedtime for 7 days; ovule 100 mg 
daily for 3 days) or oral clindamycin (500 mg twice daily 
for 7 days) appeared to be equivalent to oral (500 mg twice 
daily for 7 days) or topical metronidazole (0.75% gel 5 g 
daily for 7 days).20 However, topical clindamycin tended 
to cause a lower rate of adverse effects (metallic taste in 
the mouth, nausea, vomiting) than oral metronidazole.19 
In addition, clindamycin cream and ovules which are oil-
based might interfere with the safety of latex condoms and 
diaphragms.
Tinidazole
Tinidazole is a nitroimidazole antibiotic and an antiprotozoal 
agent that was first reported in Europe, Asia, and Latin 
America for its use in BV treatment. Trials evaluating oral 
regimens of 1–2 g daily for 1–5 days have given favorable 
results.30 Tinidazole was licensed recently in the US for the 
treatment of BV .31
Tinidazole vs placebo
A randomized controlled trial assessed the effectiveness, 
at 21–30 days after treatment, of tinidazole administered 
orally at 1 g once daily for 5 days and 2 g once daily for 
2 days, compared with placebo.32 The authors demonstrated 
superior efficacy of both tinidazole regimens to placebo in 
the treatment of BV . The cure rates were 37% for the 1 g 
once daily for 5 days group, 27% for the 2 g once daily for 
2 days group, and 5.1% in the placebo group. The FDA based 
its recent approval on these results.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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Tinidazole vs metronidazole
Based on its pharmacokinetic profile, tinidazole has 
the potential of being a highly efficacious drug for BV. 
  Compared with metronidazole, it has a higher Cmax, area 
under the curve, and steady-state serum concentration, and 
longer half-life.33 The spectrum of activity against bacteria 
associated with BV is very similar for the two agents.33 
The efficacy of two regimens of tinidazole (500 mg twice 
daily or 1 g twice daily for 7 days) was compared with 
metronidazole 500 mg twice daily for 7 days in a random-
ized trial.34 No significant   difference was found in treatment 
failure rates (Nugent score $7) between tinidazole (27% 
for the 1 g regimen and 25% for the 500 mg regimen) and 
  metronidazole (18%) at the 14-day follow-up visit. Similarly, 
short-term recurrence rates at the 2-month follow-up visit were 
not significantly different (40%, 20%, and 34%   respectively).
Tinidazole vs clindamycin
Only one study has evaluated the efficacy of a single oral 
2 g dose of tinidazole compared with 2% clindamycin 
vaginal cream for 7 days.35 At the end of the therapy, the 
women in the tinidazole group were treated with an acidic 
vaginal gel 2 g every 3 days for an additional 3 weeks. After 
1 week of treatment, the clinical cure rate (,2 Amsel’s 
criteria) was 84% in both groups with no statistical differ-
ence. At the 4-week follow-up the clinical cure rate was 
higher in the tinidazole and acidic vaginal gel group (94%) 
than that in the clindamycin group (78%) with no statisti-
cal difference. This result suggests that a single dose of 
oral tinidazole is as effective as topical clindamycin. No 
study has compared the efficacy of oral tinidazole with 
oral clindamycin.
Adverse effects
Oral tinidazole therapy has been associated with adverse 
events (yeast infection, nausea, vomiting, and bad taste in 
the mouth) such as those observed with oral metronidazole 
therapy.32
Secnidazole
Secnidazole is a nitroimidazole antibiotic with a broad 
spectrum of activity against anaerobic microorganisms and 
has a longer half-life than metronidazole.36 Used as a single-
dose oral regimen it appears effective in the treatment of 
amebiasis, giardiasis, trichomoniasis, and BV .36 It represents 
an attractive therapeutic option particularly in women whose 
likely compliance is doubtful.
Secnidazole vs metronidazole
No study has evaluated the efficacy of secnidazole compared 
with placebo. The efficacy of secnidazole was however 
compared with the mainstay of BV therapy, metronidazole. 
A randomized, double-blind, noninferiority study was 
conducted according to FDA guidance to compare the 
efficacy of a single 2 g oral dose of secnidazole compared 
with a 7-day course of 500 mg metronidazole administered 
orally twice daily.37 The secnidazole regimen was shown to 
be at least as effective as the multiple-dose metronidazole 
regimen. The therapeutic cure at the 28-day follow up was 
60% in the secnidazole group and 59% in the metronidazole 
group. Secnidazole was well tolerated and adverse events 
were similar in both groups (38% in the metronidazole group 
and 39% in the secnidazole group). Although headaches were 
rarely reported, they were more frequent in the secnidazole 
group (9% vs 4%).
Duration of oral regimens
In an attempt to reduce adverse effects, one study was con-
ducted to determine whether BV could be treated with a 
single 1 g oral dose of secnidazole with the same efficacy as 
that achieved with the conventional single 2 g oral dose. The 
women with symptomatic BV were randomized to receive 
one of the two regimens.38 The clinical cure rate was evalu-
ated after 1 week based on Amsel’s criteria. The cure rate 
was 97% using a 2 g therapy and 95% in the 1 g dose group. 
Adverse effects were reported at equal rates in both groups 
(34% and 36% respectively).
Other routes
Narayana and collaborators developed and evaluated in 
vitro vaginal gels based on ion-activated systems for the 
local release of secnidazole.39 This new formulation showed 
promise for reducing the systemic side effects and improving 
the therapeutic effects and patient compliance.
Nonantibiotic therapy
Probiotics
According to FDA and World Health Organization defini-
tions, probiotics are “live microorganisms which when 
administered in adequate amounts confer a health benefit on 
the host”.40 The mechanism by which probiotics confer such 
a health benefit is not well understood. Several hypotheses 
concerning their mechanism of action have been proposed: 
(i) as an example, Lactobacillus fermentum RC-14 has been 
reported to produce a biosurfactant containing a large number International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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of collagen-binding proteins that could inhibit pathogen 
adhesion and induce a competitive exclusion of the pathogen 
on epithelial cells; (ii) probiotics may produce antimicrobial 
compounds such as hydrogen peroxide, lactic acid, or bacte-
riocin, which inhibit pathogen growth; (iii) probiotic therapy 
may cause a mucosal modulation that enhances the host 
immune system response.41–43
Microorganisms with probiotic properties are L. rham-
nosus GR-1, L. rhamnosus Lcr 35, L. reuteri RC-14, and 
L. crispatus CTV-05.44–47 Taken orally or vaginally these 
have been shown to improve vaginal flora without any side 
effects and are of potential clinical importance.44–47 Intestinal 
passage of probiotic has the advantage of interfering with the 
natural process by which pathogens emerge from the intestine 
and ascend along the perineum to the vagina.45
The newly recognized strains L. rhamnosus L60 and 
L. fermentum L2348 have been considered for probiotics 
development due to their in vitro performance concerning 
bacteriocin production, adherence to epithelial cells, and 
coaggregation with pathogenic bacteria.48
Treatment of Bv
Evidence of reduced levels of resident Lactobacillus   species 
in BV has given rise to the concept of Lactobacillus strain 
replacement to restore the normal vaginal flora. Two recent 
reviews supported the use of probiotics,49,50 but further 
randomized controlled trials are needed before definitive 
conclusions can be made on the effectiveness of probiotics 
for the treatment of BV . One randomized study compared the 
efficacy of vaginal probiotics with vaginal metronidazole.51 
The authors suggested that the cure rate of BV after two 
intravaginal capsules of probiotics containing 109 L. rham-
nosus GR-1 and 109 L. reuteri RC-14 daily at bedtime for 
5 days was more effective than 0.75 metronidazole vaginal 
gel applied twice daily for 5 days. Symptomatic BV was 
significantly reduced at the 15-day follow-up in 85% of 
women in the probiotic group vs 45% in the metronidazole 
group. However, another recent randomized controlled trial 
comparing vaginal administration of 107 L. acidophilus 
and 0.03 mg estriol with vaginal metronidazole suggested 
equivalent cure rates at 3–7 days of follow-up with slightly 
inferior results at 1-month follow-up.52 Other studies have 
associated antibiotics with probiotics, the results of which 
vary depending on the types of probiotics and antibiotics 
used and also according to route of administration (oral or 
vaginal). Oral metronidazole therapy (500 mg twice daily for 
7 days) plus oral probiotic twice daily for 30 days (1 capsule 
containing 109 L. rhamnosus GR-1 and 109 L. reuteri RC-14) 
showed significantly increased efficacy compared with oral 
metronidazole alone.53 At the 30-day follow-up, 88% had 
normal vaginal flora in the probiotic group compared with 
40% in the placebo group. Martinez and collaborators con-
firmed that L. rhamnosus GR-1 and L. reuteri RC-14 might 
provide an adjunct to antimicrobial treatment and improve 
cure rates.54 In a similar study design, a single dose of 
tinidazole (2 g) supplemented with two capsules containing 
L. rhamnosus GR-1 and L. reuteri RC-14 every morning 
for the next 4 weeks showed significantly increased efficacy 
compared with tinidazole alone. At the 28-day follow-up, 
88% had normal vaginal flora in the probiotic group com-
pared with 50% in the placebo group. This finding was not 
confirmed among HIV-infected women.55 Those with BV 
treated by metronidazole for 10 days (400 mg administered 
orally twice daily), were randomized to receive daily oral 
capsules of probiotics L. rhamnosus GR-1 and L. reuteri 
RC-14 (2 × 109 viable organisms) or placebo for 6 months. 
No significant difference in the cure rate was found at the 
2-week follow-up and the prevalence of BV was similar in 
both groups at 25 weeks of follow-up. This study therefore 
showed that BV is more difficult to eradicate in HIV patients 
and oral probiotic alone administered daily did not suffi-
ciently improve the microbiota.
Prevention of recurrence
The second proposed use for probiotics is in preventing the 
recurrence of BV after an initial treatment. The hypothesis is 
that abnormalities of the vaginal flora often persist even in the 
absence of clinical symptoms after antimicrobial therapy.
One double-blind randomized placebo-controlled trial 
compared the efficacy of vaginal gelatine capsules (109 
L. gasseri Lba EB01-DSM 14869 and L. rhamnosus Lbp 
PB01-DSM 14870) administered for 10 days during three 
menstrual cycles with that of placebo adjunctive therapy after 
a 7-day course of daily 2% clindamycin vaginal cream.56 At 
1-month follow-up, the cure rate was 64% in the probiotic 
group and 78% in the placebo group; the difference was not 
significant. At the end of the study (6 months of follow-up) 
and for the women initially cured, 65% of the probiotic 
group had normal flora compared with 46% of the placebo 
group; the difference was significant. Vaginal probiotics 
inserted on 10 days per menstrual cycle over 3 months 
contributed significantly to the avoidance of relapse. The 
study showed that supplementary treatment of lactobacilli 
does not improve the efficacy of BV therapy during the International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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first month of treatment, but for women initially cured, the 
adjunct treatment significantly lengthens the time to relapse. 
These results were confirmed in another study reporting the 
long-term administration of a vaginal probiotic. Women 
with symptomatic BV were randomized: (1) to receive twice 
daily oral metronidazole 500 mg for 7 days; (2) to receive the 
same metronidazole regimen followed 8 days later by vaginal 
application of 40 mg of L. rhamnosus (.40,000 colony 
forming units) once a week for 6 months.57 The follow-up 
over 12 months showed an increase in abnormal vaginal 
flora from 9% 1 month after metronidazole alone to 31% at 
12 months. In the probiotic group, the rate of abnormal flora 
was similar at the beginning and at the end of the follow-up 
(4% and 9% respectively). According to the authors, this 
progressive divergence between the two groups resulted from 
the stabilization of a balanced vaginal flora in the probiotic 
group and the progressive increase in recurrence of BV in 
the group receiving metronidazole alone. The administration 
of the vaginal probiotic after oral metronidazole therapy 
may increase the cure rate during the follow-up period by 
stabilizing the vaginal ecosystem and thereby reducing the 
number of patients suffering BV recurrence.
Other authors have proposed the prophylactic use of 
probiotics in healthy women with a history of recurrent BV . 
A randomized, double-blind, placebo-controlled trial was 
conducted among healthy women who had suffered .2 BV 
episodes in the previous year.58 The women were randomized 
to receive either one vaginal capsule of probiotics (8 billion 
colony forming units of L. rhamnosus, L. acidophilus, and 
Streptococcus thermophilus) or placebo on a 7 days on, 7 days 
off, 7 days on regimen. Lower rates of BV incidence were 
reported during the 2 months after probiotic prophylaxis (16% 
for the probiotic and 45% for the placebo group) according 
to Amsel’s criteria. The 11-month follow-up consisting of a 
telephone interview suggested that women receiving probiotics 
had a lower incidence of BV symptoms than did those in 
the placebo group. Although this study was limited by the 
telephone follow-up interview that may have under-reported 
the frequency of BV symptoms, the results do suggest that 
local administration of Lactobacillus strain could therefore be a 
useful complementary tool in the management of recurrent BV . 
Other studies are now needed to validate further the efficacy 
of probiotics in the prevention of recurrent BV .
Local acidification of vaginal fluid
BV is characterized by the alkalinization of vaginal fluid 
(vaginal pH . 4.5) prompting some authors to propose cor-
recting the vaginal pH in order to treat BV . The results have 
been discordant. In two randomized double-blind clinical 
trials, vaginal acidification alone (5 mL acetic acid gel 
intravaginally twice daily for 7 days or 5 g acid-buffering 
formulation gel intravaginally once daily for 5 days) was 
an ineffective therapy for BV compared with placebo or 
metronidazole.59,60 However, in another randomized study, 
the combination of oral metronidazole 500 mg twice daily and 
5 g lactic acid vaginal gel at bedtime for 7 days was found to 
be better than metronidazole alone at promoting lactobacilli 
colonization and reducing malodorous vaginal discharge.61 
Moreover, not only was the lactic acid well tolerated but it 
also reduced recurrence of symptomatic BV .61
Emerging therapies
Antibiotics and novel vaginal  
delivery systems
Vaginal delivery of metronidazole or clindamycin is the most 
common therapy in the treatment of BV , but its efficacy is 
not optimal. Some authors are working towards improving 
existing formulations or creating new dosage forms. One 
group in Egypt working on pluronic polymers, has developed 
a hydrogel that swells in aqueous environments for use as a 
drug delivery system. This novel vaginal delivery system for 
metronidazole, improved the therapeutic efficacy compared 
with that achieved with conventional vaginal gel.62 In a pilot 
randomized trial, while similar cure rates were reported after 
1 week of treatment (85% in the new vaginal gel group and 
71.4% in the conventional vaginal gel group; P = 0.294), the 
cure rate was significantly higher after 4 weeks in the new gel 
group compared with the conventional gel group (80% and 
47%, respectively). These results suggest a novel and efficient 
long-term treatment of BV . Elsewhere, a new dosage form, 
containing metronidazole, was developed based on vaginal 
mucoadhesive tablets realized by including bioadhesive 
polymers.63 Similarly, new bioadhesive film formulations of 
clindamycin phosphate for vaginal delivery have also been 
developed.64 The in vitro properties and antibacterial activity 
of these new formulations may offer an alternative to tradi-
tional dosage forms for vaginal topical administration. The 
success of such new dosage forms, and bioadhesive products 
designed to extend the residence time of the antibiotic in the 
vaginal cavity, will not only depend on their effectiveness 
but also on their potential toxicity for epithelial cells of the 
vaginal mucosa and for resident lactobacilli.
Novel antimicrobial agents
Nifuratel, a furane-derivative, is an antiprotozoal and 
antifungal agent. Safe, well tolerated and with no known International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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teratogenic effects, it can be used in the treatment of 
many infections of the genito-urinary tract.65 Togni and 
collaborators recently compared the antimicrobial activity 
of nifuratel against G. vaginalis, A. vaginae, and lactobacilli 
with that of the two currently used antibiotics. Results suggest 
that nifuratel has a more optimum spectrum of activity, being 
highly active against G. vaginalis and A. vaginae without 
affecting lactobacilli.66 These data are promising and led the 
authors to propose nifuratel for the treatment of BV . Clinical 
studies should now be developed.
effect of antifungal therapy on Bv
Self-treatment with antifungals is widely practiced and it 
may be useful in women with Candida who are co-infected 
with BV. The general consensus is that opposing vaginal 
pH are required for the growth of C. albicans and BV , but 
because candida vulvo-vaginitis requires low acidity and 
BV requires high vaginal pH levels, this notion is incorrect. 
Indeed, Donders and collaborators reported recently that 
nine out of 142 women (roughly 6%) with symptomatic 
candidosis also had BV .67 Antifungal treatment cured the BV 
in 70% of women with simultaneous candida vaginitis. While 
antifungal treatment may have a beneficial effect on women 
with concurrent BV , it does not prevent BV from occurring in 
BV-negative women. A similar benefit of antifungal therapy 
has been reported previously in a randomized controlled 
trial,68 in which women who received ovules containing 
metronidazole and nystatin for BV had a better cure rate 
at 2 weeks of treatment than those receiving metronidazole 
0.75% gel alone (20% and 4%, respectively). Moreover, the 
benefits of combined therapy remained at 3 months of treat-
ment (52% and 33%, respectively).
Antiseptics
Essential oils from medicinal plants have strong antiseptic 
properties. Two recent studies have suggested the use 
of thymol and eugenol for BV therapy.69,70 Thymol is a 
natural monoterpene phenol found in oil of thyme, with an 
in vitro activity on G. vaginalis biofilms; and eugenol is a 
phenylpropene extracted in particular from clove oil. Both 
were applied via vaginal douche once daily for 7 days and 
resulted in a similar significant reduction in symptoms as 
that obtained with vaginal metronidazole.70 Beyond reducing 
symptoms, the effect of thymol on vaginal flora should 
however be analyzed.
Glycerol monolaurate, another antiseptic, is a safe mono-
glyceride with bactericidal properties for Gram-positive 
organisms. It is microbicidal for Candida and G. vaginalis 
in vitro and reduces both organisms without affecting vaginal 
lactobacilli in vivo when applied via vaginal gel.71 Clinical 
trials are now needed to assess the effectiveness of glycerol 
monolaurate gel in treating BV .
A recent study evaluated the efficacy of octenidine hydro-
chloride/phenoxyethanol, a local antiseptic spray, applied for 
7 or 14 days compared with 7 days of metronidazole vaginal 
tablets for BV therapy.72 The local antiseptic spray was as 
effective as the standard therapy with cure rates of 58% and 
71% at 7 days and 14 days, respectively, compared with 61% 
at 7 days with metronidazole.
A team from China has developed a temperature-sensitive 
gel containing silver nanoparticles and investigated its anti-
bacterial properties in vitro. This optimized silver nanopar-
ticle dosage form demonstrated great potential, encouraging 
further development for the clinical treatment of BV .73
Prebiotics
Another alternative for treating BV is to induce a vaginal 
flora shift from a BV- to a Lactobacillus-dominated flora by 
promoting the growth of lactobacilli. The principle behind 
prebiotics is to provide nutriments that stimulate the growth 
of lactobacilli. Oligosaccharides can selectively promote 
the growth of lactobacilli that in turn generate lactic acid to 
lower the vaginal pH and secrete antibacterial substances that 
inhibit the adhesion and replication of the anaerobic bacteria.74 
Some authors have proposed the topical application of a gel 
containing sucrose, a disaccharide of glucose and fructose, to 
treat BV . A Phase III clinical trial was conducted including 
women with symptomatic BV who were randomly assigned 
into three groups for vaginal application of sucrose (5 g), 
metronidazole (0.75%), and placebo gels, twice daily for 
5 consecutive days.75 The therapeutic cure rates (according 
to FDA guidelines) evaluated 21–35 days after the start 
of treatment were 61%, 67%, and 7%, respectively, for 
sucrose, metronidazole, and placebo gel groups. These results 
suggest that sucrose has a therapeutic cure rate similar to the 
metronidazole gel. Interestingly, at the intermediate visit 
(7–10 days after the start of treatment), the therapeutic cure 
rate was statistically higher for the sucrose group (83%) than 
for the metronidazole group (71.3%) and the placebo group 
(0.9%). The evaluation of lactobacilli based on the Nugent 
score at the 5–7 days visit showed significantly higher levels 
of lactobacilli in the sucrose gel group compared with the 
metronidazole group. These results suggest that by promoting 
the growth of lactobacilli, sucrose gel restores normal vaginal 
flora more rapidly than does metronidazole. However, while 
the rate of adverse events after sucrose gel was found to be International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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similar with that found in the other groups, treatment with 
sucrose would be expected also to promote the development 
of candidosis.
Current strategies
Symptomatic Bv
BV is the most prevalent cause of vaginal discharge or 
odor. The most recent recommendations for the treatment 
of symptomatic BV to relieve these vaginal symptoms were 
issued in 2010 by the US Centers for Disease Control.76 
The recommended regimens in pregnant and nonpregnant 
women are reported in Table 1. First-line treatment includes 
metronidazole or clindamycin. Alcohol consumption should 
be avoided throughout the 7-day treatment with systemic 
metronidazole and 1 day after. For women presenting side 
effects, the vaginal route may be recommended. Choice of 
treatment should be carefully considered among users of 
condoms and diaphragms, since weakening of the latex can 
occur for up to 5 days after applying the oil-based clindamy-
cin cream. Of note is the recent introduction of tinidazole 
as an alternative to metronidazole and clindamycin. During 
treatment regimens, women should be advised to avoid 
unprotected sex. In addition, vaginal douching that promotes 
vaginal recurrences should be discouraged. Routine treatment 
of sex partners is not considered necessary.
Asymptomatic Bv
The benefits gained from screening asymptomatic BV in 
order to prevent adverse outcomes are doubtful. While the 
association between BV and preterm birth is well established, 
data are inconsistent on the screening and treatment of 
asymptomatic BV during pregnancy in order to prevent 
preterm birth.77 Despite this, since 2008, the US Preventive 
Services Task Force recommends against the routine 
screening for BV in asymptomatic pregnant women. For 
pregnant women at high risk for preterm birth, the evidence is 
insufficient to make any recommendation about screening.78 
The Centers for Disease Control and Prevention have made 
similar recommendations.76
Women with BV also have an elevated risk of postop-
erative infection, especially after surgical abortion in the first 
trimester. Additional prophylactic antibiotics given to women 
with asymptomatic BV have not been shown to reduce the risk. 
As such, evidence to support the usefulness of pre-procedure 
screening for BV is lacking.79 The Society of Family Planning 
does not recommend routine screening for asymptomatic BV 
but recommends the routine use of antibiotic prophylaxis, 
preferably with doxycycline, before surgical abortion.
Current recommendations do not advocate treatment 
of asymptomatic BV in order to reduce the acquisition 
of sexually transmitted diseases or HIV . Few studies have 
investigated the benefit of treatment. The first two random-
ized studies yielded conflicting results on the impact of 
screening and treatment of sexually transmitted infections, 
including BV , to prevent HIV acquisition.80,81 However, a 
pilot study demonstrated that treatment of asymptomatic 
BV with metronidazole among HIV-infected women had an 
impact on HIV-1 shedding in the genital tract.82 Furthermore, 
a prospective randomized study suggested that twice-weekly 
prophylactic use of intravaginal metronidazole gel resulted in 
significantly fewer cases of chlamydial infection.83 Based on 
these data, consideration should be given to routine treatment 
of women with asymptomatic BV; however, further studies 
are warranted to confirm these findings.
Treatment failure
Unfortunately, relapse is frequent after antibiotic treatment. 
The recurrence rate has been estimated at 58% 12 months 
after oral metronidazole therapy.84 There are several   possible 
reasons for the treatment failure. Firstly, the strains of 
A. vaginae have a variable susceptibility for metronidazole 
with some even showing a high-level resistance.85 Secondly, 
resistance to antimicrobial agent may be due to the survival 
of A. vaginae and G. vaginalis as a biofilm on the vaginal 
epithelium after therapy.9 Lastly, possible reinfection may 
explain the high recurrence rate as suggested by the highest 
cure rate observed among women who abstained from having 
sex or consistently used condoms during treatment.86
No recommendations and limited data are available on 
optimal management strategies for women with recurring BV 
Table  1  Regimens  for  the  treatment  of  bacterial  vaginosis 
according to the US Centers for Disease Control76
Three recommended regimens
1. Metronidazole 500 mg orally twice daily for 7 days
2.   Metronidazole gel 0.75%, 1 full application (5 g) intravaginally, once 
daily for 5 days
3.   Clindamycin cream 2%, 1 full application (5 g) intravaginally at bedtime 
for 7 days
Three alternative regimens
1. Tinidazole 2 g orally once daily for 2 days
2. Tinidazole 1 g orally once daily for 5 days
3. Clindamycin 300 mg orally twice daily for 7 days
4. Clindamycin ovules 100 mg intravaginally once at bedtime for 3 days
Three recommended regimens for pregnant women
1. Metronidazole 500 mg orally twice daily for 7 days
2. Metronidazole 250 mg orally 3 times daily for 7 days
3. Clindamycin 300 mg orally twice daily for 7 daysInternational Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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or in whom treatment failed. It appears as though treatment 
of recurrent BV may require a combination of modalities.87 
Providers should firstly counsel women with recurrent BV 
to minimize their number of male sex partners, although 
few data support recommending other behavioral changes.88 
Then, in the absence of curative therapy,   practitioners should 
resort to retreating each individual episode of BV with a 
different treatment regimen or extending the duration of 
therapy from a single dose to a 7-day regimen if needed.25,89 
For women with high risk of recurrence of symptomatic 
BV, others have suggested suppressive therapy after an 
initial treatment of BV . Topical boric acid associated with 
suppressive metronidazole gel or the use of acetic acid 
vaginal gel has been recommended to keep the vaginal pH 
at #4.5.90,91 Similarly, the use of lactic acid gel after an initial 
metronidazole treatment should reduce the recurrence of 
symptomatic BV .92 Long-term follow-up periods are needed 
to validate this therapeutic option.
Finally, several studies have evaluated the clinical 
and microbiological efficacy of probiotics to treat and to 
prevent the recurrence of BV. Despite the need for more 
clinical studies, probiotics should be considered as part of 
the approach to disease prevention, and as an adjunct to 
antimicrobial treatment.92
Conclusion
Several antimicrobial agents have been used to treat 
symptomatic BV. Until recently, the mainstay therapy 
consisted of either metronidazole or clindamycin. A recent 
alternative has been the use of tinidazole. Probiotics should 
be seriously considered as part of the approach to disease 
prevention, and as an adjunct to antimicrobial treatment. 
Current recommendations do not advocate treatment of 
asymptomatic BV .
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